jueves, 12 de enero de 2017

USA: Sanofi, Lilly & Novo "pricing collusion"

The implicated firms have strongly denied the claims, stating that their actions have been perfectly legal and that the price rises are nothing more than representative of a highly competitive market and reimbursement plans which put “an unfair burden on people with diabetes.

Publicar un comentario